Mason Marks, Rebecca W. Brendel, Carmel Shachar, I. Glenn Cohen, JAMA Psychiatry Analysis of the challenges of designing and implementing psychedelic informed consent practices revealed 7 essential components, including the possibility of short- and long-term perceptual disturbances, potential personality changes and altered metaphysical beliefs, the limited role of reassuring physical touch, the potential for patient abuse or coercion, the role and risks…
Treat addiction with psychedelics?
Harvard Gazette // Petrie-Flom Center Despite promise of success stories from patients in recovery, Law School panel cautions that research is lacking on benefits vs. risks…
What psychedelics legalisation and decriminalisation looks like around the world
BBC // Petrie-Flom Center Featuring Petrie-Flom’s Mason Marks in BBC: Psychedelics see increased legalisation and decriminalisation globally as treatment usages expand….
The Project on Psychedelics Law and Regulation (POPLAR)
Ongoing Petrie-Flom Center The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. Launched in summer 2021 with a generous grant from the Saisei Foundation, the Project on Psychedelics Law and Regulation (POPLAR) at the…
Why regulators may toss cold water on buzz over psychedelics
The Harvard Gazette // Petrie-Flom Center The Gazette spoke with Mason Marks, a visiting professor at Harvard Law School who leads the School’s Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. Marks wrote about the potential for collision between state and federal laws in a December…
FDA to review MDMA-assisted therapy, a milestone for psychedelics
The Washington Post // Petrie-Flom Center By Daniel Gilbert & David Ovalle, featuring Mason Marks…
State-Regulated Psychedelics on a Collision Course With FDA
Mason Marks, JAMA Interest in researching and commercializing psychedelic medicines is growing. Substances such as psilocybin and 3,4-methylenedioxymethamphetamine show potential for treating conditions including depression and posttraumatic stress disorder. The Food and Drug Administration (FDA) may soon approve psychedelics for these and other indications….
Massachusetts weighs the legalization of psychedelics — and the future of tripping
Boston Globe // Petrie-Flom Center A proposed ballot measure stirs deeper questions about how we should approach hallucinogenic drugs. By David Scharfenberg, featuring Mason Marks…
Psychedelic Assisted Therapy: Last Week Tonight with John Oliver
HBO // Petrie-Flom Center Last Week Tonight with John Oliver, Psychedelic Assisted Therapy, featuring Mason Marks and I. Glenn Cohen…
A Macro View of Microdosing
Bill of Health // Petrie-Flom Center This symposium, along with its companion moderated panel discussion, gathered experts on the science, law, and business of microdosing….